Welcome to our dedicated page for Cryo-Cell Intl news (Ticker: CCEL), a resource for investors and traders seeking the latest updates and insights on Cryo-Cell Intl stock.
Cryo-Cell International, Inc. (CCEL) is a NYSE American–listed company focused on cellular processing, cryogenic storage, and cord blood banking. The company describes itself as the world’s first private cord blood bank to separate and store stem cells, with operations that span private cord blood and cord tissue banking, a public cord blood banking program in partnership with Duke University, and technology and biostorage offerings such as PrepaCyte-CB and ExtraVault.
This news page aggregates company-issued updates and regulatory disclosures that affect Cryo-Cell’s business and capital structure. Readers can follow periodic financial results, where the company breaks out revenue from processing and storage fees, public banking activities, and product revenue. Dividend-related announcements are also a recurring theme, including the initiation of regular quarterly cash dividends, changes in dividend levels, and decisions not to declare dividends in certain quarters, often linked to profitability, capital requirements, and strategic priorities.
In addition to earnings and dividend news, Cryo-Cell’s releases highlight developments tied to its license agreement with Duke University, research and development spending related to clinical studies and manufacturing capabilities, and the launch and positioning of ExtraVault for biostorage and distribution services. Disclosures about strategic reviews, such as the pause of initiatives relating to a possible sale or merger of the company, provide further context on corporate strategy.
Investors and observers who want to monitor how Cryo-Cell’s cord blood banking operations, cellular therapy ambitions, and biostorage services evolve over time can use this page to review a chronological record of earnings releases, dividend decisions, strategic updates, and other material announcements.
Cryo-Cell International, Inc. (OTC: CCEL) reported its third-quarter financial results for fiscal 2020, revealing consolidated revenues of $8.1 million, slightly down from $8.2 million in Q3 2019. Net income was reported at $784,000, or $0.10 per share, a decline from $1,116,000, or $0.14 per share, in the prior year. Notably, the company incurred a one-time expense of $1,070,900 due to the termination of the Erie Group Revenue Sharing Agreement. Despite challenges, management expressed optimism regarding a licensing agreement with Duke University.